AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Farxiga / Forxiga (dapagliflozin) by Year
Farxiga / Forxiga (dapagliflozin) — Emerging Markets product sales ($M) ($M)
AstraZeneca Farxiga / Forxiga (dapagliflozin): $3,324M in FY2025, up 16.5% from a year earlier.
Where the FY2025 figure comes from
“|| Farxiga | 8,400 | 10 | 9 | 1,730 | (1) | 3,324 | 17 | 18 | 2,941 | 12 | 8 | 405 | (3) | (3)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Farxiga / Forxiga (dapagliflozin) — Emerging Markets product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,324 | +16.5% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 2,853 | +29.0% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 2,211 | +32.8% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 1,665 | +39.3% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 1,195 | +74.2% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 686 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Breakdown
What makes up farxiga / Forxiga (dapagliflozin)
Cite this data
StockData. (2026). AstraZeneca Farxiga / Forxiga (dapagliflozin) ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-farxiga-em
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.